Skip to main content
Erschienen in: Diabetologia 3/2015

01.03.2015 | Position Statement

Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

verfasst von: Silvio E. Inzucchi, Richard M. Bergenstal, John B. Buse, Michaela Diamant, Ele Ferrannini, Michael Nauck, Anne L. Peters, Apostolos Tsapas, Richard Wender, David R. Matthews

Erschienen in: Diabetologia | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Excerpt

In 2012, the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) published a position statement on the management of hyperglycaemia in patients with type 2 diabetes [1, 2]. This was needed because of an increasing array of anti-hyperglycaemic drugs and growing uncertainty regarding their proper selection and sequence. Because of a paucity of comparative effectiveness research on long-term treatment outcomes with many of these medications, the 2012 publication was less prescriptive than prior consensus reports. We previously described the need to individualise both treatment targets and treatment strategies, with an emphasis on patient-centred care and shared decision-making, and this continues to be our position, although there are now more head-to-head trials that show slight variance between agents with regard to glucose-lowering effects. Nevertheless, these differences are often small and would be unlikely to reflect any definite differential effect in an individual patient. …
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Inzucchi SE, Bergenstal RM, Buse JB et al (2012) Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35:1364–1379PubMedCentralPubMedCrossRef Inzucchi SE, Bergenstal RM, Buse JB et al (2012) Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35:1364–1379PubMedCentralPubMedCrossRef
2.
Zurück zum Zitat Inzucchi SE, Bergenstal RM, Buse JB et al (2012) Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55:1577–1596PubMedCrossRef Inzucchi SE, Bergenstal RM, Buse JB et al (2012) Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55:1577–1596PubMedCrossRef
3.
Zurück zum Zitat Stratton IM, Adler AI, Neil HA et al (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405–412PubMedCentralPubMedCrossRef Stratton IM, Adler AI, Neil HA et al (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405–412PubMedCentralPubMedCrossRef
4.
Zurück zum Zitat UKPDS Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:837–853CrossRef UKPDS Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:837–853CrossRef
5.
Zurück zum Zitat Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577–1589PubMedCrossRef Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577–1589PubMedCrossRef
6.
Zurück zum Zitat Gerstein HC, Miller ME, Byington RP et al (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545–2559PubMedCrossRef Gerstein HC, Miller ME, Byington RP et al (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545–2559PubMedCrossRef
7.
Zurück zum Zitat Vasilakou D, Karagiannis T, Athanasiadou E et al (2013) Sodium–glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 159:262–274PubMedCrossRef Vasilakou D, Karagiannis T, Athanasiadou E et al (2013) Sodium–glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 159:262–274PubMedCrossRef
8.
Zurück zum Zitat Stenlöf K, Cefalu WT, Kim KA et al (2013) Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 15:372–382PubMedCentralPubMedCrossRef Stenlöf K, Cefalu WT, Kim KA et al (2013) Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 15:372–382PubMedCentralPubMedCrossRef
9.
Zurück zum Zitat Schernthaner G, Gross JL, Rosenstock J et al (2013) Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 36:2508–2515PubMedCentralPubMedCrossRef Schernthaner G, Gross JL, Rosenstock J et al (2013) Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 36:2508–2515PubMedCentralPubMedCrossRef
10.
Zurück zum Zitat Roden M, Weng J, Eilbracht J et al (2013) Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 1:208–219PubMedCrossRef Roden M, Weng J, Eilbracht J et al (2013) Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 1:208–219PubMedCrossRef
11.
Zurück zum Zitat Nauck MA, Del Prato S, Meier JJ et al (2011) Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 34:2015–2022PubMedCentralPubMedCrossRef Nauck MA, Del Prato S, Meier JJ et al (2011) Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 34:2015–2022PubMedCentralPubMedCrossRef
12.
Zurück zum Zitat Cefalu WT, Leiter LA, Yoon KH et al (2013) Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 382:941–950PubMedCrossRef Cefalu WT, Leiter LA, Yoon KH et al (2013) Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 382:941–950PubMedCrossRef
13.
Zurück zum Zitat Bakris GL, Fonseca VA, Sharma K, Wright EM (2009) Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int 75:1272–1277PubMedCrossRef Bakris GL, Fonseca VA, Sharma K, Wright EM (2009) Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int 75:1272–1277PubMedCrossRef
14.
Zurück zum Zitat Ferrannini E, Solini A (2012) SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol 8:495–502PubMedCrossRef Ferrannini E, Solini A (2012) SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol 8:495–502PubMedCrossRef
15.
Zurück zum Zitat Rosenstock J, Seman LJ, Jelaska A et al (2013) Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metab 15:1154–1160PubMedCrossRef Rosenstock J, Seman LJ, Jelaska A et al (2013) Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metab 15:1154–1160PubMedCrossRef
16.
Zurück zum Zitat Chino Y, Samukawa Y, Sakai S et al (2014) SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dispos 35:391–404PubMedCentralPubMedCrossRef Chino Y, Samukawa Y, Sakai S et al (2014) SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dispos 35:391–404PubMedCentralPubMedCrossRef
17.
Zurück zum Zitat Nyirjesy P, Sobel JD, Fung A et al (2014) Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Curr Med Res Opin 30:1109–1119PubMedCrossRef Nyirjesy P, Sobel JD, Fung A et al (2014) Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Curr Med Res Opin 30:1109–1119PubMedCrossRef
18.
Zurück zum Zitat Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF (2013) Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complicat 27:479–484PubMedCrossRef Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF (2013) Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complicat 27:479–484PubMedCrossRef
19.
Zurück zum Zitat Monami M, Nardini C, Mannucci E (2014) Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 16:457–466PubMedCrossRef Monami M, Nardini C, Mannucci E (2014) Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 16:457–466PubMedCrossRef
20.
Zurück zum Zitat Weir MR, Kline I, Xie J, Edwards R, Usiskin K (2014) Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR). Curr Med Res Opin 30:1759–1768PubMedCrossRef Weir MR, Kline I, Xie J, Edwards R, Usiskin K (2014) Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR). Curr Med Res Opin 30:1759–1768PubMedCrossRef
21.
Zurück zum Zitat FDA briefing document (2013) Invokana (canagliflozin) tablets. [NDA 204042], US Food and Drug Administration FDA briefing document (2013) Invokana (canagliflozin) tablets. [NDA 204042], US Food and Drug Administration
22.
Zurück zum Zitat Neal B, Perkovic V, de Zeeuw D et al (2013) Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—a randomized placebo-controlled trial. Am Heart J 166:217–223.e11PubMedCrossRef Neal B, Perkovic V, de Zeeuw D et al (2013) Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—a randomized placebo-controlled trial. Am Heart J 166:217–223.e11PubMedCrossRef
23.
Zurück zum Zitat Balaji V, Seshiah V, Ashtalakshmi G, Ramanan SG, Janarthinakani M (2014) A retrospective study on finding correlation of pioglitazone and incidences of bladder cancer in the Indian population. Indian J Endocrinol Metab 18:425–427PubMedCentralPubMedCrossRef Balaji V, Seshiah V, Ashtalakshmi G, Ramanan SG, Janarthinakani M (2014) A retrospective study on finding correlation of pioglitazone and incidences of bladder cancer in the Indian population. Indian J Endocrinol Metab 18:425–427PubMedCentralPubMedCrossRef
24.
Zurück zum Zitat Kuo HW, Tiao MM, Ho SC, Yang CY (2014) Pioglitazone use and the risk of bladder cancer. Kaohsiung J Med Sci 30:94–97PubMedCrossRef Kuo HW, Tiao MM, Ho SC, Yang CY (2014) Pioglitazone use and the risk of bladder cancer. Kaohsiung J Med Sci 30:94–97PubMedCrossRef
25.
Zurück zum Zitat Wei L, MacDonald TM, Mackenzie IS (2013) Pioglitazone and bladder cancer: a propensity score matched cohort study. Br J Clin Pharmacol 75:254–259PubMedCentralPubMedCrossRef Wei L, MacDonald TM, Mackenzie IS (2013) Pioglitazone and bladder cancer: a propensity score matched cohort study. Br J Clin Pharmacol 75:254–259PubMedCentralPubMedCrossRef
26.
Zurück zum Zitat Dormandy JA, Charbonnel B, Eckland DJ et al (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366:1279–1289PubMedCrossRef Dormandy JA, Charbonnel B, Eckland DJ et al (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366:1279–1289PubMedCrossRef
27.
Zurück zum Zitat Colhoun HM, Livingstone SJ, Looker HC et al (2012) Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs. Diabetologia 55:2929–2937PubMedCentralPubMedCrossRef Colhoun HM, Livingstone SJ, Looker HC et al (2012) Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs. Diabetologia 55:2929–2937PubMedCentralPubMedCrossRef
28.
Zurück zum Zitat Scirica BM, Bhatt DL, Braunwald E et al (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369:1317–1326PubMedCrossRef Scirica BM, Bhatt DL, Braunwald E et al (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369:1317–1326PubMedCrossRef
29.
Zurück zum Zitat Scirica BM, Braunwald E, Raz I et al (2014) Heart failure, saxagliptin and diabetes mellitus: observations from the SAVOR - TIMI 53 randomized trial. Circulation 130:1579–1588PubMedCrossRef Scirica BM, Braunwald E, Raz I et al (2014) Heart failure, saxagliptin and diabetes mellitus: observations from the SAVOR - TIMI 53 randomized trial. Circulation 130:1579–1588PubMedCrossRef
30.
Zurück zum Zitat White WB, Cannon CP, Heller SR et al (2013) Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369:1327–1335PubMedCrossRef White WB, Cannon CP, Heller SR et al (2013) Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369:1327–1335PubMedCrossRef
31.
Zurück zum Zitat White WB, Pratley R, Fleck P et al (2013) Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus. Diabetes Obes Metab 15:668–673PubMedCrossRef White WB, Pratley R, Fleck P et al (2013) Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus. Diabetes Obes Metab 15:668–673PubMedCrossRef
32.
Zurück zum Zitat Egan AG, Blind E, Dunder K et al (2014) Pancreatic safety of incretin-based drugs—FDA and EMA assessment. N Engl J Med 370:794–797PubMedCrossRef Egan AG, Blind E, Dunder K et al (2014) Pancreatic safety of incretin-based drugs—FDA and EMA assessment. N Engl J Med 370:794–797PubMedCrossRef
33.
Zurück zum Zitat Salpeter SR, Greyber E, Pasternak GA, Salpeter EE (2010) Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev (4):CD002967. doi:10.1002/14651858.CD002967.pub4 Salpeter SR, Greyber E, Pasternak GA, Salpeter EE (2010) Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev (4):CD002967. doi:10.​1002/​14651858.​CD002967.​pub4
34.
35.
Zurück zum Zitat Nye HJ, Herrington WG (2011) Metformin: the safest hypoglycaemic agent in chronic kidney disease? Nephron Clin Pract 118:c380–c383PubMedCrossRef Nye HJ, Herrington WG (2011) Metformin: the safest hypoglycaemic agent in chronic kidney disease? Nephron Clin Pract 118:c380–c383PubMedCrossRef
36.
Zurück zum Zitat Pilmore HL (2010) Review: metformin: potential benefits and use in chronic kidney disease. Nephrology 15:412–418PubMedCrossRef Pilmore HL (2010) Review: metformin: potential benefits and use in chronic kidney disease. Nephrology 15:412–418PubMedCrossRef
37.
Zurück zum Zitat Lu WR, Defilippi J, Braun A (2013) Unleash metformin: reconsideration of the contraindication in patients with renal impairment. Ann Pharmacother 47:1488–1497PubMedCrossRef Lu WR, Defilippi J, Braun A (2013) Unleash metformin: reconsideration of the contraindication in patients with renal impairment. Ann Pharmacother 47:1488–1497PubMedCrossRef
38.
Zurück zum Zitat National Institute for Health and Care Excellence (2009) Type 2 diabetes: the management of type 2 diabetes [CG87]. NICE, London National Institute for Health and Care Excellence (2009) Type 2 diabetes: the management of type 2 diabetes [CG87]. NICE, London
39.
Zurück zum Zitat Groop PH, Del Prato S, Taskinen MR et al (2014) Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment. Diabetes Obes Metab 16:560–568PubMedCentralPubMedCrossRef Groop PH, Del Prato S, Taskinen MR et al (2014) Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment. Diabetes Obes Metab 16:560–568PubMedCentralPubMedCrossRef
40.
Zurück zum Zitat Phung OJ, Sobieraj DM, Engel SS, Rajpathak SN (2014) Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes Metab 16:410–417PubMedCrossRef Phung OJ, Sobieraj DM, Engel SS, Rajpathak SN (2014) Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes Metab 16:410–417PubMedCrossRef
41.
Zurück zum Zitat Musso G, Gambino R, Cassader M, Pagano G (2012) A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med 44:375–393PubMedCrossRef Musso G, Gambino R, Cassader M, Pagano G (2012) A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med 44:375–393PubMedCrossRef
42.
Zurück zum Zitat Goring S, Hawkins N, Wygant G et al (2014) Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis. Diabetes Obes Metab 16:433–442PubMedCrossRef Goring S, Hawkins N, Wygant G et al (2014) Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis. Diabetes Obes Metab 16:433–442PubMedCrossRef
43.
Zurück zum Zitat Bosi E, Ellis GC, Wilson CA, Fleck PR (2011) Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study. Diabetes Obes Metab 13:1088–1096PubMedCrossRef Bosi E, Ellis GC, Wilson CA, Fleck PR (2011) Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study. Diabetes Obes Metab 13:1088–1096PubMedCrossRef
44.
Zurück zum Zitat Holman RR, Thorne KI, Farmer AJ et al (2007) Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 357:1716–1730PubMedCrossRef Holman RR, Thorne KI, Farmer AJ et al (2007) Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 357:1716–1730PubMedCrossRef
45.
Zurück zum Zitat Eng C, Kramer CK, Zinman B, Retnakaran R (2014) Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet. doi:10.1016/S0140-6736(14)61335-0 Eng C, Kramer CK, Zinman B, Retnakaran R (2014) Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet. doi:10.​1016/​S0140-6736(14)61335-0
46.
Zurück zum Zitat Diamant M, Nauck MA, Shaginian R et al (2014) Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. Diabetes Care 37:2763–2773PubMedCrossRef Diamant M, Nauck MA, Shaginian R et al (2014) Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. Diabetes Care 37:2763–2773PubMedCrossRef
47.
Zurück zum Zitat Buse JB, Bergenstal RM, Glass LC et al (2011) Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 154:103–112PubMedCrossRef Buse JB, Bergenstal RM, Glass LC et al (2011) Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 154:103–112PubMedCrossRef
48.
Zurück zum Zitat Balena R, Hensley IE, Miller S, Barnett AH (2013) Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature. Diabetes Obes Metab 15:485–502PubMedCentralPubMedCrossRef Balena R, Hensley IE, Miller S, Barnett AH (2013) Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature. Diabetes Obes Metab 15:485–502PubMedCentralPubMedCrossRef
49.
Zurück zum Zitat Charbonnel B, Bertolini M, Tinahones FJ, Domingo MP, Davies M (2014) Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis. J Diabetes Complicat 28:880–886PubMedCrossRef Charbonnel B, Bertolini M, Tinahones FJ, Domingo MP, Davies M (2014) Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis. J Diabetes Complicat 28:880–886PubMedCrossRef
50.
Zurück zum Zitat Lane W, Weinrib S, Rappaport J, Hale C (2014) The effect of addition of liraglutide to high-dose intensive insulin therapy: a randomized prospective trial. Diabetes Obes Metab 16:827–832PubMedCrossRef Lane W, Weinrib S, Rappaport J, Hale C (2014) The effect of addition of liraglutide to high-dose intensive insulin therapy: a randomized prospective trial. Diabetes Obes Metab 16:827–832PubMedCrossRef
51.
Zurück zum Zitat Davidson MB, Raskin P, Tanenberg RJ, Vlajnic A, Hollander P (2011) A stepwise approach to insulin therapy in patients with type 2 diabetes mellitus and basal insulin treatment failure. Endocr Pract 17:395–403PubMedCrossRef Davidson MB, Raskin P, Tanenberg RJ, Vlajnic A, Hollander P (2011) A stepwise approach to insulin therapy in patients with type 2 diabetes mellitus and basal insulin treatment failure. Endocr Pract 17:395–403PubMedCrossRef
52.
Zurück zum Zitat Rosenstock J, Jelaska A, Frappin G et al (2014) Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care 37:1815–1823PubMedCrossRef Rosenstock J, Jelaska A, Frappin G et al (2014) Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care 37:1815–1823PubMedCrossRef
53.
Zurück zum Zitat Charbonnel B, DeFronzo R, Davidson J et al (2010) Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19). J Clin Endocrinol Metab 95:2163–2171PubMedCrossRef Charbonnel B, DeFronzo R, Davidson J et al (2010) Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19). J Clin Endocrinol Metab 95:2163–2171PubMedCrossRef
54.
Zurück zum Zitat Shah PK, Mudaliar S, Chang AR et al (2011) Effects of intensive insulin therapy alone and in combination with pioglitazone on body weight, composition, distribution and liver fat content in patients with type 2 diabetes. Diabetes Obes Metab 13:505–510PubMedCentralPubMedCrossRef Shah PK, Mudaliar S, Chang AR et al (2011) Effects of intensive insulin therapy alone and in combination with pioglitazone on body weight, composition, distribution and liver fat content in patients with type 2 diabetes. Diabetes Obes Metab 13:505–510PubMedCentralPubMedCrossRef
55.
Zurück zum Zitat Davidson MB, Navar MD, Echeverry D, Duran P (2010) U-500 regular insulin: clinical experience and pharmacokinetics in obese, severely insulin-resistant type 2 diabetic patients. Diabetes Care 33:281–283PubMedCentralPubMedCrossRef Davidson MB, Navar MD, Echeverry D, Duran P (2010) U-500 regular insulin: clinical experience and pharmacokinetics in obese, severely insulin-resistant type 2 diabetic patients. Diabetes Care 33:281–283PubMedCentralPubMedCrossRef
56.
Zurück zum Zitat Hawa MI, Buchan AP, Ola T et al (2014) LADA and CARDS: a prospective study of clinical outcome in established adult-onset autoimmune diabetes. Diabetes Care 37:1643–1649PubMedCrossRef Hawa MI, Buchan AP, Ola T et al (2014) LADA and CARDS: a prospective study of clinical outcome in established adult-onset autoimmune diabetes. Diabetes Care 37:1643–1649PubMedCrossRef
57.
Zurück zum Zitat Zampetti S, Campagna G, Tiberti C et al (2014) High GADA titer increases the risk of insulin requirement in LADA: a 7-years of follow-up (NIRAD Study 7). Eur J Endocrinol 171:697–704PubMedCrossRef Zampetti S, Campagna G, Tiberti C et al (2014) High GADA titer increases the risk of insulin requirement in LADA: a 7-years of follow-up (NIRAD Study 7). Eur J Endocrinol 171:697–704PubMedCrossRef
58.
Zurück zum Zitat Nathan DM, Buse JB, Kahn SE et al (2013) Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). Diabetes Care 36:2254–2261PubMedCentralPubMedCrossRef Nathan DM, Buse JB, Kahn SE et al (2013) Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). Diabetes Care 36:2254–2261PubMedCentralPubMedCrossRef
59.
Zurück zum Zitat Ismail-Beigi F, Moghissi E, Tiktin M, Hirsch IB, Inzucchi SE, Genuth S (2011) Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med 154:554–559PubMedCrossRef Ismail-Beigi F, Moghissi E, Tiktin M, Hirsch IB, Inzucchi SE, Genuth S (2011) Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med 154:554–559PubMedCrossRef
60.
Zurück zum Zitat Chiasson JL, Gomis R, Hanefeld M, Josse RG, Karasik A, Laakso M; STOP-NIDDM Trial Research Group (1998) The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Diabetes Care 21:1720–1725CrossRef Chiasson JL, Gomis R, Hanefeld M, Josse RG, Karasik A, Laakso M; STOP-NIDDM Trial Research Group (1998) The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Diabetes Care 21:1720–1725CrossRef
61.
Zurück zum Zitat UKPDS Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospect Diabetes Study (UKPDS) Group Lancet 352:854–865 UKPDS Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospect Diabetes Study (UKPDS) Group Lancet 352:854–865
62.
Zurück zum Zitat Gaziano JM, Cincotta AH, O'Connor CM et al (2010) Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care 33:1503–1508PubMedCentralPubMedCrossRef Gaziano JM, Cincotta AH, O'Connor CM et al (2010) Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care 33:1503–1508PubMedCentralPubMedCrossRef
Metadaten
Titel
Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
verfasst von
Silvio E. Inzucchi
Richard M. Bergenstal
John B. Buse
Michaela Diamant
Ele Ferrannini
Michael Nauck
Anne L. Peters
Apostolos Tsapas
Richard Wender
David R. Matthews
Publikationsdatum
01.03.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Diabetologia / Ausgabe 3/2015
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-014-3460-0

Weitere Artikel der Ausgabe 3/2015

Diabetologia 3/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

VHF-Ablation nützt wohl nur bei reduzierter Auswurfleistung

02.05.2024 Ablationstherapie Nachrichten

Ob die Katheterablation von Vorhofflimmern bei Patienten mit Herzinsuffizienz die Komplikationsraten senkt, scheint davon abzuhängen, ob die Auswurfleistung erhalten ist oder nicht. Das legen die Ergebnisse einer Metaanalyse nahe.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.